Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases

Stock Information for Cue Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cue Biopharma Inc.

Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
Cue Biopharma Announces Pricing of $10 Million Public Offering
Cue Biopharma Announces Proposed Public Offering
Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors
Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates
Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.